Dark
Streaming/Mobile
Old Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:04:15 EDT Fri 29 Mar 2024
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR Search
SEDAR Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login to Stockwatch
News for U:XFOR from 2023-03-30 to 2024-03-29 - 30 items
News Releases
In The News
Other
CA
US
Date
Sym
Price
Type
Headline
2024-03-21 06:01
U
U:XFOR
News Release
200
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
2024-03-12 08:00
U
U:XFOR
News Release
200
X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024
2024-03-01 16:05
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-01 16:05
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing ‚ Rule 5635(c)(4)
2023-12-09 12:00
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023
2023-12-04 16:05
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-10 08:00
U
U:XFOR
News Release
200
X4 Pharmaceuticals to Participate in Upcoming November Investor Conferences
2023-11-09 06:01
U
U:XFOR
News Release
200
X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and ‚ Provides Corporate Updates
2023-11-02 08:00
U
U:XFOR
News Release
200
X4 Pharmaceuticals to Report Third-Quarter 2023 Financial Results and Host a Conference Call and Webcast on November 9, 2023
2023-11-01 16:05
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-10-31 08:00
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM Syndrome
2023-10-18 08:00
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Appointment of Industry Veteran R. Keith Woods to Board of Directors
2023-10-02 16:05
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing ‚ Rule 5635(c)(4)
2023-09-19 08:00
U
U:XFOR
News Release
200
X4 Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
2023-09-06 08:00
U
U:XFOR
News Release
200
X4 Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
2023-09-05 08:00
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Submission of New Drug Application (NDA) to U.S. FDA for Mavorixafor in WHIM Syndrome
2023-09-01 16:05
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-10 06:05
U
U:XFOR
News Release
200
X4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results, Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program
2023-08-08 16:05
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Industry Veteran Dr. Christophe Arbet-Engels to Join as Chief Medical Officer
2023-08-03 08:00
U
U:XFOR
News Release
200
X4 Pharmaceuticals Closes $115 Million Loan Facility with Hercules Capital
2023-08-02 08:01
U
U:XFOR
News Release
200
X4 Pharmaceuticals to Report Second-Quarter 2023 Financial Results and Host a Conference Call and Webcast on August 10, 2023
2023-06-30 16:05
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing ‚ Rule 5635(c)(4)
2023-06-13 08:00
U
U:XFOR
News Release
200
X4 Pharmaceuticals Expected to Join Russell 3000 ‚ ® Index
2023-06-02 16:05
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing ‚ Rule 5635(c)(4)
2023-05-16 16:01
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Duration of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome
2023-05-16 08:30
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market
2023-05-04 06:05
U
U:XFOR
News Release
200
X4 Pharmaceuticals Reports First-Quarter 2023 Financial Results and Provides Corporate Update
2023-04-26 08:01
U
U:XFOR
News Release
200
X4 Pharmaceuticals to Report First-Quarter 2023 Financial Results and Host a Conference Call and Webcast on May 4, 2023
2023-04-12 08:00
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Late-Breaking Abstract of WHIM Phase 3 Clinical Data Accepted for Oral Presentation at the 2023 Annual Meeting of the Clinical Immunology Society (CIS)
2023-04-04 16:05
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing ‚ Rule 5635(c)(4)